Amgen's new Horizon products bolster top line despite continued Tepezza struggles
Fierce Pharma
MAY 3, 2024
Much of the boost can be attributed to sales of products acquired in Amgen’s $27.8 . | The buzz about Amgen’s obesity prospects overshadowed the company’s solid work on the top line as revenue came in at $7.4 billion for a 22% increase. billion buyout of Horizon Therapeutics, which was completed early in the fourth quarter of last year.
Let's personalize your content